1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Malignant Mesothelioma - Pipeline Review, H1 2015

Malignant Mesothelioma - Pipeline Review, H1 2015

  • May 2015
  • -
  • Global Markets Direct
  • -
  • 303 pages

Malignant Mesothelioma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Malignant Mesothelioma - Pipeline Review, H1 2015’, provides an overview of the Malignant Mesothelioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Malignant Mesothelioma - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Malignant Mesothelioma Overview 9
Therapeutics Development 10
Pipeline Products for Malignant Mesothelioma - Overview 10
Pipeline Products for Malignant Mesothelioma - Comparative Analysis 11
Malignant Mesothelioma - Therapeutics under Development by Companies 12
Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes 17
Malignant Mesothelioma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Malignant Mesothelioma - Products under Development by Companies 23
Malignant Mesothelioma - Products under Investigation by Universities/Institutes 27
Malignant Mesothelioma - Companies Involved in Therapeutics Development 28
Aduro BioTech, Inc. 28
Advantagene, Inc. 29
Aeolus Pharmaceuticals, Inc. 30
Amphera BV 31
Applied Research using OMIC Sciences, S.L. 32
arGEN-X BV 33
ArQule, Inc. 34
AVEO Pharmaceuticals, Inc. 35
Bayer AG 36
Biogen, Inc. 37
Bionomics Limited 38
Biotecnol, Inc. 39
Boehringer Ingelheim GmbH 40
Boston Biomedical, Inc. 41
Bristol-Myers Squibb Company 42
Calithera Biosciences, Inc. 43
CanBas Co., Ltd. 44
Concordia Healthcare Corp. 45
CritiTech, Inc. 46
Deciphera Pharmaceuticals, LLC 47
Eagle Pharmaceuticals, Inc. 48
Eisai Co., Ltd. 49
Eli Lilly and Company 50
EnGeneIC Ltd 51
F. Hoffmann-La Roche Ltd. 52
Five Prime Therapeutics, Inc. 53
Formula Pharmaceuticals, Inc. 54
Genelux Corporation 55
GlaxoSmithKline plc 56
Juno Therapeutics Inc. 57
Kyowa Hakko Kirin Co., Ltd. 58
MedImmune, LLC 59
Merck and Co., Inc. 60
Merck KGaA 61
Millennium Pharmaceuticals, Inc. 62
MolMed S.p.A. 63
Morphotek, Inc. 64
Novartis AG 65
Oncos Therapeutics Ltd. 66
Oxford BioMedica plc 67
Pfizer Inc. 68
Pharma Mar, S.A. 69
Polaris Pharmaceuticals, Inc. 70
Sellas Inc. 71
SentoClone International AB 72
Synta Pharmaceuticals Corp. 73
VasGene Therapeutics, Inc. 74
Verastem, Inc. 75
Virttu Biologics Limited 76
Y's Therapeutics Co., Ltd. 77
Malignant Mesothelioma - Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Target 80
Assessment by Mechanism of Action 83
Assessment by Route of Administration 86
Assessment by Molecule Type 88
Drug Profiles 90
AEOL-10150 - Drug Profile 90
alisertib - Drug Profile 93
amatuximab - Drug Profile 97
anetumab ravtansine - Drug Profile 100
ARGX-110 - Drug Profile 102
ascrinvacumab - Drug Profile 105
AV-203 - Drug Profile 106
avelumab - Drug Profile 107
BERTA - Drug Profile 109
BG-00001 - Drug Profile 110
BIW-8962 - Drug Profile 111
BMS-986148 - Drug Profile 112
BNC-105 - Drug Profile 113
CB-839 - Drug Profile 114
CBP-501 - Drug Profile 116
Cell Therapy 1 for Oncology - Drug Profile 118
CRS-207 - Drug Profile 119
defactinib hydrochloride - Drug Profile 122
Dendritic Cell Therapy for Cancer - Drug Profile 124
Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile 125
DP-3975 - Drug Profile 126
DPV-001 - Drug Profile 127
E-7449 - Drug Profile 129
FP-1039 - Drug Profile 130
FPI-01 - Drug Profile 132
ganetespib - Drug Profile 134
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 138
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 139
GLONC-1 - Drug Profile 140
GSK-2256098 - Drug Profile 143
HSV-1716 - Drug Profile 144
iCasp9M28z - Drug Profile 146
JTCR-016 - Drug Profile 147
LY-3023414 - Drug Profile 148
MesoCancerVac - Drug Profile 150
MesoCART - Drug Profile 151
Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile 152
MV-NIS - Drug Profile 154
napabucasin - Drug Profile 156
NGR-hTNF - Drug Profile 159
nintedanib - Drug Profile 163
ONCOS-102 - Drug Profile 168
Oshadi D + Oshadi R - Drug Profile 169
paclitaxel - Drug Profile 170
pegargiminase - Drug Profile 171
pembrolizumab - Drug Profile 174
pemetrexed disodium - Drug Profile 181
porfimer sodium - Drug Profile 183
Recombinant Protein to Antagonize EphB4 Receptor for Oncology - Drug Profile 184
RG-7787 - Drug Profile 186
Sentoclone - Drug Profile 187
Small Molecules to Inhibit Bcl-2 Survival Proteins for Cancer - Drug Profile 189
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 190
TargomiRs - Drug Profile 191
Tb-535 - Drug Profile 193
tivantinib - Drug Profile 194
trabectedin - Drug Profile 197
tremelimumab - Drug Profile 201
TroVax - Drug Profile 203
Vaccine for Cancer - Drug Profile 206
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 207
Vaccine to Target WT1 for Cancer - Drug Profile 208
VS-5584 - Drug Profile 209
YS-110 - Drug Profile 211
Malignant Mesothelioma - Recent Pipeline Updates 212
Malignant Mesothelioma - Dormant Projects 284
Malignant Mesothelioma - Discontinued Products 286
Malignant Mesothelioma - Product Development Milestones 287
Featured News and Press Releases 287
Appendix 297
Methodology 297
Coverage 297
Secondary Research 297
Primary Research 297
Expert Panel Validation 297
Contact Us 297
Disclaimer 298

List of Tables
Number of Products under Development for Malignant Mesothelioma, H1 2015 15
Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Comparative Analysis by Unknown Stage Development, H1 2015 27
Products under Development by Companies, H1 2015 28
Products under Development by Companies, H1 2015 (Contd..1) 29
Products under Development by Companies, H1 2015 (Contd..2) 30
Products under Development by Companies, H1 2015 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Malignant Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2015 33
Malignant Mesothelioma - Pipeline by Advantagene, Inc., H1 2015 34
Malignant Mesothelioma - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 35
Malignant Mesothelioma - Pipeline by Amphera BV, H1 2015 36
Malignant Mesothelioma - Pipeline by Applied Research using OMIC Sciences, S.L., H1 2015 37
Malignant Mesothelioma - Pipeline by arGEN-X BV, H1 2015 38
Malignant Mesothelioma - Pipeline by ArQule, Inc., H1 2015 39
Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 40
Malignant Mesothelioma - Pipeline by Bayer AG, H1 2015 41
Malignant Mesothelioma - Pipeline by Biogen, Inc., H1 2015 42
Malignant Mesothelioma - Pipeline by Bionomics Limited, H1 2015 43
Malignant Mesothelioma - Pipeline by Biotecnol, Inc., H1 2015 44
Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 45
Malignant Mesothelioma - Pipeline by Boston Biomedical, Inc., H1 2015 46
Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2015 47
Malignant Mesothelioma - Pipeline by Calithera Biosciences, Inc., H1 2015 48
Malignant Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2015 49
Malignant Mesothelioma - Pipeline by Concordia Healthcare Corp., H1 2015 50
Malignant Mesothelioma - Pipeline by CritiTech, Inc., H1 2015 51
Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 52
Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 53
Malignant Mesothelioma - Pipeline by Eisai Co., Ltd., H1 2015 54
Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H1 2015 55
Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2015 56
Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 57
Malignant Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H1 2015 58
Malignant Mesothelioma - Pipeline by Formula Pharmaceuticals, Inc., H1 2015 59
Malignant Mesothelioma - Pipeline by Genelux Corporation, H1 2015 60
Malignant Mesothelioma - Pipeline by GlaxoSmithKline plc, H1 2015 61
Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc., H1 2015 62
Malignant Mesothelioma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 63
Malignant Mesothelioma - Pipeline by MedImmune, LLC, H1 2015 64
Malignant Mesothelioma - Pipeline by Merck and Co., Inc., H1 2015 65
Malignant Mesothelioma - Pipeline by Merck KGaA, H1 2015 66
Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 67
Malignant Mesothelioma - Pipeline by MolMed S.p.A., H1 2015 68
Malignant Mesothelioma - Pipeline by Morphotek, Inc., H1 2015 69
Malignant Mesothelioma - Pipeline by Novartis AG, H1 2015 70
Malignant Mesothelioma - Pipeline by Oncos Therapeutics Ltd., H1 2015 71
Malignant Mesothelioma - Pipeline by Oxford BioMedica plc, H1 2015 72
Malignant Mesothelioma - Pipeline by Pfizer Inc., H1 2015 73
Malignant Mesothelioma - Pipeline by Pharma Mar, S.A., H1 2015 74
Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 75
Malignant Mesothelioma - Pipeline by Sellas Inc., H1 2015 76
Malignant Mesothelioma - Pipeline by SentoClone International AB, H1 2015 77
Malignant Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H1 2015 78
Malignant Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H1 2015 79
Malignant Mesothelioma - Pipeline by Verastem, Inc., H1 2015 80
Malignant Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2015 81
Malignant Mesothelioma - Pipeline by Y's Therapeutics Co., Ltd., H1 2015 82
Assessment by Monotherapy Products, H1 2015 83
Assessment by Combination Products, H1 2015 84
Number of Products by Stage and Target, H1 2015 86
Number of Products by Stage and Mechanism of Action, H1 2015 89
Number of Products by Stage and Route of Administration, H1 2015 92
Number of Products by Stage and Molecule Type, H1 2015 94
Malignant Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2015 217
Malignant Mesothelioma - Dormant Projects, H1 2015 289
Malignant Mesothelioma - Dormant Projects (Contd..1), H1 2015 290
Malignant Mesothelioma - Discontinued Products, H1 2015 291

List of Figures
Number of Products under Development for Malignant Mesothelioma, H1 2015 15
Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 17
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Products, H1 2015 26
Assessment by Monotherapy Products, H1 2015 83
Number of Products by Top 10 Targets, H1 2015 85
Number of Products by Stage and Top 10 Targets, H1 2015 85
Number of Products by Top 10 Mechanism of Actions, H1 2015 88
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 88
Number of Products by Top 10 Routes of Administration, H1 2015 91
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 92
Number of Products by Top 10 Molecule Types, H1 2015 93
Number of Products by Stage and Top 10 Molecule Types, H1 2015 93

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US - Forecast

  • November 2016
    4 pages
  • Cancer  

  • United States  

    New Zealand  

View report >

Cancer Statistics in the UK

  • November 2016
    51 pages
  • Cancer  

    Therapy  

    Oncology  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US

  • November 2016
    8 pages
  • Cancer  

  • United States  

View report >

Related Market Segments :

Cancer
Lung Cancer
Therapy
Pharmaceutical

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.